KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Equity Income (2020 - 2023)

Ginkgo Bioworks Holdings (DNA) has disclosed Equity Income for 4 consecutive years, with -$1.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Equity Income fell 111.19% year-over-year to -$1.1 million, compared with a TTM value of -$2.6 million through Dec 2023, up 93.98%, and an annual FY2023 reading of -$2.6 million, up 93.98% over the prior year.
  • Equity Income was -$1.1 million for Q4 2023 at Ginkgo Bioworks Holdings, down from -$67000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $59.9 million in Q4 2021 and bottomed at -$39.7 million in Q3 2021.
  • Average Equity Income over 4 years is -$4.0 million, with a median of -$5.8 million recorded in 2022.
  • The sharpest move saw Equity Income surged 368.11% in 2021, then tumbled 180.05% in 2022.
  • Year by year, Equity Income stood at -$22.3 million in 2020, then soared by 368.11% to $59.9 million in 2021, then tumbled by 83.31% to $10.0 million in 2022, then tumbled by 111.19% to -$1.1 million in 2023.
  • Business Quant data shows Equity Income for DNA at -$1.1 million in Q4 2023, -$67000.0 in Q2 2023, and -$1.4 million in Q1 2023.